Community-Based Exercise Oncology: Real-World Evidence of High Adherence, Improved Quality of Life and Cost-Effectiveness Across the Cancer Continuum

January 20, 2026 updated by: University of Castilla-La Mancha

This prospective observational cohort study evaluates a community-based supervised exercise oncology program delivered in real-world settings in Madrid, Spain. The program is designed for adults with a cancer diagnosis across the cancer continuum, including survivors, patients undergoing active treatment, individuals receiving hormonotherapy, and patients with metastatic disease.

Participants take part in a structured multimodal exercise program combining aerobic, resistance, and functional training, delivered in supervised group-based sessions either in person or through synchronous online formats. The primary aims of the study are to assess program adherence, health-related quality of life, fatigue, and cost-effectiveness, expressed as quality-adjusted life years (QALYs). Secondary outcomes include cardiorespiratory fitness, muscular strength, functional capacity, physical activity levels, body composition, and psychological well-being.

Assessments are conducted at baseline and every four months over a 12-month follow-up period. This study provides real-world evidence on the feasibility, clinical impact, and economic value of community-based exercise oncology programs across different stages of the cancer trajectory.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

This study is a prospective observational cohort analysis of adults with a confirmed cancer diagnosis participating in a community-based supervised exercise oncology program in Madrid, Spain. Participants are referred by oncology specialists or self-referred with medical clearance to engage in moderate-intensity physical exercise.

The intervention consists of supervised multimodal exercise sessions lasting approximately 75 minutes, including warm-up, combined aerobic and resistance training, and cool-down periods. Aerobic training is prescribed using heart rate reserve and perceived exertion scales, while resistance training includes free-weight and functional exercises targeting major muscle groups. Sessions are delivered in small groups either face-to-face or via synchronous online platforms, with individualized progression and safety monitoring.

Participants undergo standardized assessments at baseline and at 4, 8, and 12 months. Primary outcomes include adherence to supervised exercise sessions, health-related quality of life, fatigue, and cost-effectiveness measured through quality-adjusted life years derived from EQ-5D instruments. Secondary outcomes include estimated cardiorespiratory fitness, muscular strength, functional capacity tests, physical activity behavior, body composition, and psychological outcomes.

The study aims to generate real-world evidence on the feasibility, effectiveness, and economic impact of integrating structured exercise programs into community-based cancer care across different clinical stages of disease.

Study Type

Observational

Enrollment (Actual)

492

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Madrid
      • Madrid, Madrid, Spain, 28007
        • Ejercicio y Cáncer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

  • Adults (≥18) with a confirmed cancer diagnosis.
  • At any stage of the disease.
  • Who have been medically cleared to participate in supervised exercise.

Description

Inclusion Criteria:

  • Age ≥18 years.
  • Confirmed diagnosis of cancer, at any stage of disease.
  • Medical clearance to perform moderate-intensity physical exercise.
  • Able to ambulate independently without assistive devices.
  • Willingness to attend supervised exercise sessions for a follow-up period of at least 12 months.

Exclusion Criteria:

  • Absolute medical contraindications to exercise (e.g., unstable angina, uncontrolled arrhythmias, severe anemia, acute infection, or thrombosis).
  • Unstable metastatic bone disease without radiologic and/or oncologic clearance.
  • Cognitive or functional impairment preventing safe participation in the exercise program.
  • Concurrent participation in another structured exercise intervention or clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
cancer survivors
Adults with a previous cancer diagnosis who had completed primary oncological treatment and were participating in a community-based supervised exercise oncology program.
Active Cancer Treatment
Adults with a cancer diagnosis undergoing active oncological treatment, excluding hormonotherapy, who were participating in the supervised community-based exercise oncology program.
Hormone therapy
Adults with a cancer diagnosis receiving hormonotherapy who were enrolled in the supervised community-based exercise oncology program.
Metastatic
Adults with metastatic cancer participating in the supervised community-based exercise oncology program, with medical clearance for moderate-intensity exercise.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Percentage of supervised exercise sessions completed out of scheduled sessions.
Baseline, 4 months, 8 months, and 12 months.
Health-related quality of life (FACT-G)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Health-related quality of life (units on a scale) assessed using the Functional Assessment of Cancer Therapy - General (FACT-G)
Baseline, 4 months, 8 months, and 12 months.
Fatigue (FACT-F)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Fatigue (units on a scale) assessed using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACT-F).
Baseline, 4 months, 8 months, and 12 months.
Quality-adjusted life years (QALYs)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Quality-adjusted life years calculated by integrating EQ-5D utility scores collected at multiple time points over the 12-month follow-up period. Repeated EQ-5D measurements are aggregated to derive a single QALY value per participant.
Baseline, 4 months, 8 months, and 12 months.
Barriers to participation
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Using a structured questionnaire based on previously published frameworks on determinants of adherence in cancer survivors.
Baseline, 4 months, 8 months, and 12 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Estimated VO₂max
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Estimated maximal oxygen uptake (VO₂max) assessed using the Bruce treadmill protocol and Mackenzie equation.
Baseline, 4 months, 8 months, and 12 months.
Muscular strength
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Upper- and lower-limb muscular strength (kg) estimated using submaximal tests to estimate one-repetition maximum (1RM).
Baseline, 4 months, 8 months, and 12 months.
Functional capacity
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Functional capacity assessed using the 6-Minute Walk Test (6MWT) in meters.
Baseline, 4 months, 8 months, and 12 months.
Functional capacity
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Functional capacity assessed using the 30-second Sit-to-Stand test (repetitions)
Baseline, 4 months, 8 months, and 12 months.
Body weight (kg)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Body weight assessed by bioelectrical impedance analysis using the Tanita MC-601F.
Baseline, 4 months, 8 months, and 12 months.
Body Fat Percentage (%)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Body Fat Percentage (%) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Baseline, 4 months, 8 months, and 12 months.
Fat Mass (kg)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Fat Mass (kg) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Baseline, 4 months, 8 months, and 12 months.
Lean Mass Percentage (%)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Lean Mass Percentage (%) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Baseline, 4 months, 8 months, and 12 months.
Lean Mass (kg)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Lean Mass (kg) assessed by bioelectrical impedance analysis (Tanita MC-601F).
Baseline, 4 months, 8 months, and 12 months.
Physical activity
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Physical activity levels assessed using the International Physical Activity Questionnaire (IPAQ). The IPAQ estimates total physical activity expressed as metabolic equivalent minutes per week (MET-min/week), calculated from self-reported frequency, duration, and intensity of physical activity. Scores range from 0 MET-min/week to no upper limit, with higher values indicating higher levels of physical activity.
Baseline, 4 months, 8 months, and 12 months.
Anxiety (HADS-A)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Symptoms of anxiety (units on a scale) assessed using the Hospital Anxiety Scale (HADS-A) The HADS-A consists of 7 items scored from 0 to 3, yielding a total score ranging from 0 to 21, with higher scores indicating greater severity of anxiety symptoms.
Baseline, 4 months, 8 months, and 12 months.
Depression (HADS-D)
Time Frame: Baseline, 4 months, 8 months, and 12 months.
Depressive symptoms assessed using the Hospital Anxiety and Depression Scale - Depression subscale (HADS-D). The HADS-D consists of 7 items scored from 0 to 3, yielding a total score ranging from 0 to 21, with higher scores indicating greater severity of depressive symptoms.
Baseline, 4 months, 8 months, and 12 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Soraya Casla-Barrio, PhD., Director of the Exercise and Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2022

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

July 31, 2026

Study Registration Dates

First Submitted

December 22, 2025

First Submitted That Met QC Criteria

January 20, 2026

First Posted (Actual)

January 26, 2026

Study Record Updates

Last Update Posted (Actual)

January 26, 2026

Last Update Submitted That Met QC Criteria

January 20, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • COHORT-EYC-22-25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to ethical and privacy considerations, as the dataset includes sensitive health information collected in a real-world community-based program. Data are stored in accordance with local data protection regulations and institutional policies.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Subscribe